Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04156087
Title Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer (MIMIPAC)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Baki Topal
Age Groups: adult | senior
Covered Countries BEL

No variant requirements are available.